Insight
What the NHS 10-Year Health Plan means for women and where it “falls short”

The government’s 10-year plan for the NHS promises bold transformation, with a move towards digital innovation, and more focus on prevention over treatment, but does it go far enough to address the UK’s gender health gap?
Health Secretary Wes Streeting has revealed his vision for the UK’s public healthcare system, promising to transform the NHS over the next decade, in the government’s Fit for the Future report.
From a renewed focus on maternity care, to ambitions to eliminate cervical cancer by 2040, the government says its 10-year plan will play a fundamental role in delivering its commitment to women’s health “never again being ignored”.
Currently, the UK has the largest gender health gap in the G20, with the average woman spending nearly a quarter of her life in poor health compared to a fifth for men.
Yet while the plan has been described as a “strong foundation”, crucial details about how its promises will be delivered are yet to be published, and some say the lack of specific action to address the gender health gap mean it may “fall short” for women.
Community, prevention and digitisation— what the government has promised
The NHS 10 year plan is underpinned by three key pillars; a move from hospital to community, sickness to prevention and from analogue to digital.
A focus on prevention, rather than sickness, promises to deliver better access to screening, and allow better use of health data to enable more predictive and pre-emptive care.
Plans to increase uptake of HPV vaccinations aim to help the NHS reach its ambitious target of eliminating cervical cancer by 2040. Meanwhile, universal newborn genomic testing and an introduction to polygenic risk scoring will be used to identify potential risks to child and maternal health early and help predict susceptibility to diseases.
The government has also committed to a national independent investigation into maternity and neonatal services, setting out plans for the establishment of a national maternity and neonatal taskforce, chaired by the Secretary of State, as well as a national action plan co-produced with bereaved families.
Placing more focus on neighbourhood health centres, rather than hospital treatment, will enable more people to access health services closer to home, according to the proposals, while an increased focus on the digitalisation of the NHS aims to make services faster, more convenient, and more personalised.
All patients will gain access to a single, digital health record, and the NHS app will be expanded allowing patients to book appointments, manage long-term conditions, reproductive health and medications, and coordinate care for children or elderly family members.
My Children, a digital alternative to what has been known for decades in maternity care as the ‘red book’ also aims to make it easier to manage children’s healthcare and medical records.
Speaking following the publication of the plan on Thursday 3 July, Streeting described this as a “meaningful advancement”, giving parents “practical tools when they need them most”.
“This isn’t just about convenience… It’s about recognising the realities of modern parenthood and removing unnecessary barriers to good healthcare,” he said.
“From offering timely, advice about feeding and weaning in those first months to providing guidance about adolescent mental health years later, this digital companion adapts to your family’s changing needs.”
Where the plan “falls short” on women’s health
The plan’s proposals for maternity care have been welcomed by the Royal College of Obstetricians and Gynaecologists (RCOG), with many women not receiving the “personalised, high-quality care they deserve”.
However, president, Professor Ranee Thakar, has suggested it lacks clarity on how it will address many of the the issues contributing to the gender health gap.
“While the plan lays strong foundations, it falls short in pledging to eliminate the gender health gap that is costing women years of life and good health,” Prof Thakar said in statement on Thursday.
“Today’s plan must mark a move away from treating women’s health as a collection of niche issues towards offering women excellent, joined-up care across their life course, with investment in the women’s health workforce, Femtech and research.”
Despite the fact that one in three women in the UK will suffer from a reproductive or gynaecological problem, less than 2.5 per cent of publicly funded research is dedicated solely to reproductive health.
Thakar added: “A huge opportunity may be missed without a clear focus on delivering better for women. We would like to see the Women’s Health Strategy for England reset quickly, to work alongside the 10-Year Plan in driving improvements in women’s health access, experiences and outcomes, particularly for minority ethnic women and those in the most socially deprived areas.”
The Women’s Health Strategy, developed and published in 2022, promised to address the inequalities in the health and care system, by providing better care for menstrual and gynaecological conditions, expanding women’s health hubs, improving maternity care and accelerating research into women’s health.
Some have been critical of the roll out of the strategy, accusing the former Conservative government of using it as a “short-term vote winner” and failing to fund it properly. A total of £25m was allocated to fund one-stop-shop women’s health hubs across the country for two years, compared to £240m which was spent on the Rwanda deportation scheme.
The role of women’s health hubs
The RCOG has called for the acceleration of women’s health hubs, which its believes could play a “crucial role” in establishing the neighbourhood care model which Streeting has promised in his 10-year plan.
Hubs bring healthcare services together, making the referral process easier and allowing women to see see different specialists, therapists and diagnostic teams under one roof, which can be beneficial for those managing complex symptoms or chronic health issues.
However according to Dr Nikki Kanani, a GP specialising in women’s health and a former director of primary care for NHS England, many are still in the pilot stage and services are stretched due to a lack of healthcare professionals trained in women’s health.
“What we need to do is follow through on the commitment of the strategy, to understand what good looks like and invest in scaling that,” she tells Femtech World.
“We need to treat hubs as a core part of the system, not just a side project,” she tells Femtech World.
“We need to understand what good looks like and invest in scaling that. That needs to be clearly set out with nationally-protected funding and ICB accountability. We need to upscale across primary care, we need roles that reflect the breadth of the knowledge that’s needed, and we need protected time for clinicians to work in these spaces.”
Dr Kanani also believes hubs also need to move beyond focusing on reproductive issues to other areas of healthcare where women are traditonally “dismissed” and “deprioritised”, such as cardiovascular care and mental health services.
Alongside this, incentivised targets for gender and ethnicity gaps in diagnosis, referrals and outcomes, as well as system-wide women’s health leads, could be practical next steps to ensure women’s health is prioritised across the NHS, Dr Kanani says.
Increased investment in private innovators
The government has promised to embrace technologies such as AI, genomics, wearables and robotics, to improve clinical outcomes and reduce clinician workload, which could see a shift towards more public-private partnerships in the NHS and more investment in private innovators.
Dr Kanani says this would be “welcome”, but innovators seeking NHS partnerships, especially in the women’s health space, will need to consider factors such as regulator requirements, responsible data-gathering and the practicalities of training clinicians.
“Any femtech company innovating a point of care solution should be thinking not just of their tool, but also how their tool improves decision-making, documentation and communication, she says.
“We can roll out thousands of tools, but frontline clinicians are understandably time-poor. Part of your job as a responsible innovator, is to say ‘here is my solution, let’s train you and make sure it’s easy to use and deploy’.”
Equity needs more than strategy
The promises of the 10-year plan are bold and ambitious, but how effective it will be— especially for women— remains to be seen.
A planned chapter explaining how the proposed changes would be delivered was not published alongside the rest of the plan on Thursday, and is now expected later this year.
Dr Kanani says how the plan is delivered will be crucial in determining how far it goes to improve women’s healthcare.
“There are some important steps in the 10-year plan, but health equity for women, particularly those from minoritised, marginalised and underserved communities, won’t be achieved through strategy alone. We need a really deep, system-wide culture shift,” she says.
“Equity needs more than just the narrative of equal access, it needs tailored design. Care models, research, workforce, all need to be actively built around these women and communities.”
Dr Kanani adds: “It could be transformational for women, but only if it’s designed intentionally around the realities of women’s lives.”
News
From Hologic to Ark Surgical: Why Joseph LaBruzzo is betting on the future of women’s surgical innovation

After more than two decades leading organisations at some of the world’s most respected medical device companies, including Hologic, SenoRx Breast Care, and BTL Industries, Joseph B. LaBruzzo is embarking on a new chapter as President & CEO of U.S. Operations and Board Member at Ark Surgical.
We sat down with Joseph to discuss what drew him to Ark Surgical, why he believes women’s surgical innovation is entering a transformative era, and what it takes to bring meaningful technologies from concept to standard of care.
You have held leadership positions at some of the biggest names in MedTech. What attracted you to Ark Surgical?
Throughout my career, I’ve been fortunate to work with organisations that developed technologies capable of changing the standard of care.
What attracted me to Ark Surgical is the opportunity to help address a meaningful unmet need in gynecologic surgery with an innovation that has the potential to improve patient outcomes while preserving the benefits of minimally invasive surgery.
Opportunities like that don’t come along very often.
FemTech World recently highlighted that many women remain unaware of gynecologic cancers and that unexpected diagnoses continue to have a profound impact on patients and families.
How has your own experience shaped the way you think about innovation in women’s health?
Earlier in my career, I witnessed many women receive life-changing cancer diagnoses.
Those experiences stayed with me and reinforced my belief that if there’s an opportunity to reduce risk through better innovation, it’s one worth pursuing.
That’s one of the reasons I was drawn to Ark Surgical.
The vast majority of minimally invasive gynecologic procedures are performed for conditions believed to be benign. Unfortunately, in rare cases, pathology later reveals an unexpected malignancy.
LapBox was designed with a proprietary dual-wall tissue containment system to help facilitate contained specimen retrieval and minimise the risk of tissue spillage during laparoscopic procedures.
I believe innovations like this can help surgeons manage the unexpected while preserving the many benefits of minimally invasive surgery for women.
Women’s health has gained significant momentum in recent years, yet surgical innovation often receives less attention than diagnostics or therapeutics. Why do you think that is?
Women’s health has historically been underfunded and underserved across many areas of medicine, and surgery is no exception.
While we’ve seen tremendous advances in diagnostics and pharmaceuticals, there are still important opportunities to improve the surgical experience for both physicians and patients.
Innovation that enhances safety, efficiency, and outcomes has the potential to make a lasting impact.
What excites you most about LapBox?
LapBox addresses a very real challenge that gynecologic surgeons face during minimally invasive procedures.
It was thoughtfully designed to integrate seamlessly into the surgical workflow while providing an added layer of confidence when tissue retrieval is required.
I believe technologies that solve real clinical challenges in a practical way have the greatest potential to become part of the standard of care.
What do you see as the biggest unmet needs in minimally invasive gynecologic surgery today?
The future of surgery isn’t simply about making procedures less invasive. It’s about making them smarter and safer.
Surgeons need technologies that integrate seamlessly into their workflow while helping them navigate increasingly complex clinical situations.
Every advancement that helps reduce risk while preserving the benefits of minimally invasive surgery has the potential to improve outcomes for both physicians and patients.
That’s where I believe the greatest opportunities for innovation exist.
As you take on this new role, what are your priorities over the next 12 months?
Our focus over the next 12 months is to build a strong foundation for growth. That means expanding physician partnerships, driving early clinical adoption, growing our team, and ensuring that more surgeons have access to technologies like LapBox.
At the same time, we’re focused on building strategic relationships with investors, healthcare systems, and industry partners that support our long-term vision.
What advice would you give entrepreneurs building the next generation of women’s health companies?
Start with a real clinical problem and never lose sight of the patient.
Great technology alone isn’t enough. You also need strong clinical evidence, physician advocates, and a clear market strategy. The companies that succeed are the ones that bring all of those pieces together while remaining focused on improving patient care.
About Joseph B. LaBruzzo
As President & CEO of U.S. Operations and Board Member, Joseph LaBruzzo is leading Ark Surgical’s U.S. growth strategy, physician partnerships, strategic investment initiatives, and organisational expansion, supporting the company’s mission to advance safer minimally invasive gynecologic surgery through innovative technologies.
Insight
Cancer cells secretly hijacking fertility protein to survive chemo, research finds

Cancer cells may hijack a fertility protein to repair damaged DNA and survive chemotherapy, research suggests.
The findings could point to a way of making existing cancer treatments more effective.
SYCP1 is a protein normally involved in producing sperm and eggs.
Researchers at the University of Liverpool found that the protein, previously thought to work only in reproduction, can be reactivated in cancer cells, where it helps tumours survive and grow.
SYCP1 usually helps chromosomes pair during meiosis, the form of cell division that produces reproductive cells.
In cancer cells, however, the protein appears to take on another role. It enters the nucleus, the cell’s control centre, binds directly to DNA and regulates genes involved in cell division and DNA repair.
DNA repair is how cells fix damage to their genetic code. In cancer, this process can help tumour cells survive treatment.
The researchers found that removing SYCP1 made cancer cells much more sensitive to chemotherapy drugs that damage DNA.
The findings suggest cancers may use SYCP1 to repair damage caused by treatment and continue growing.
Dr Urszula McClurg, lecturer in biochemistry, cell and systems biology at the University of Liverpool, said: “Our findings show that cancer cells can hijack proteins that normally exist only in reproductive tissues and give them completely new jobs.
“Understanding these unexpected functions opens up exciting opportunities to develop new treatments that make existing cancer therapies more effective.”
The work challenges the long-held belief that proteins active only in fertility have no biological relevance outside the reproductive system.
Researchers say these specialised proteins could provide new treatment targets across many types of cancer.
The study also offers a new view of how cancers evolve by repurposing developmental and reproductive processes.
The findings highlight SYCP1 as a candidate for future precision cancer therapies, which are treatments based on the specific biology of a patient’s cancer.
News
What “women’s healthmaxxing” means for patient trust and the femtech industry

Women’s health has become one of the most searched and shared topics online, from cycle syncing and cortisol management to menopause hacks, supplements, hormone testing and clinician-creator content.
That surge in attention, sometimes dubbed “healthmaxxing,” is changing how women find, evaluate and act on health information, and it is starting to reshape the relationship between patients, clinicians and the companies building products for this market.
For providers, the shift means patients are arriving better informed but also more exposed to unverified claims, putting pressure on clinicians to engage with online narratives rather than dismiss them.
For femtech and pharma companies, it opens a route to reach and educate consumers at scale, but also raises the stakes on credibility: products and messaging that ride the trend without clinical grounding risk eroding the trust the industry has spent years building.
Investors are watching the same dynamic from a different angle.
Attention-driven demand can be a signal of where the next wave of femtech growth will come from, but distinguishing genuine clinical need from viral momentum is increasingly part of due diligence.
The net effect is a widening gap between companies that treat cultural attention as a distribution channel for credible, evidence-based care, and those that risk being swept up in trends with little clinical substance behind them.
How that gap plays out will shape patient trust, clinical relationships and commercial opportunity across the women’s health industry for years to come.
These themes will be explored in more depth in an upcoming webinar, “Women’s Healthmaxxing: The Opportunity & Risks of Cultural Attention for the Women’s Health Industry,” hosted by the Women’s Health Innovation Summit (WHIS), featuring Ellen Wilcox (Listen Ventures), Jessica Bell van der Wal (Frame Fertility), Dr. Tosin Sotubo-Ajayi (NHS, BBC and more) and Nora Lansen (Elektra Health).
Register free for the webinar on 23 July 2026 at https://events.virtualpro.com/womens-health-series-webinar-july-2026/registration
News1 week agoNew menopause drug approved for use by NHS in Scotland
Hormonal health1 week agoStardust period tracker shares health data, study reveals
News3 days agoZero Candida market set to reach over US$2 billion by 2030 – report
News1 week agoWomen’s health draws record $1.55bn in equity as capital spreads beyond the mega-rounds
Mental health2 weeks agoSSRIs may lower heat intolerance in women with depression – study
News2 weeks agoAvni Wellness secures US$470k funding
Insight2 weeks agoSoftening ovaries could extend fertility as women age, study suggests
Entrepreneur1 week agoOnto Health acquires diagnostics software company Levy Health













